Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects

HIV 感染者的疫苗和单克隆抗体研究

• 批准号: 8745627
• 负责人: Barney Graham
• 金额: $ 53.11万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745627
• 关键词: Active immunity; Adverse effects; Anti-Retroviral Agents; Antibodies; Clinic; Clinical; Clinical Research; Clinical Trials; Conduct Clinical Trials; Dose; Goals; HIV; HIV Infections; HIV-1; Immune response; Immunotherapeutic agent; Infection; Infection Control; Medication Management; Monoclonal Antibodies; Passive Immunity; Phase; Prevention; Regimen; Research Project Grants; Therapeutic Studies; United States National Institutes of Health; Vaccines; base; human monoclonal antibodies; method development; vaccine candidate; volunteer

Summary: This clinical research project is for clinical trials related to active immunity (vaccines) and passive immunity (monoclonal antibodies) directed against HIV that are evaluated in HIV-infected volunteers through clinical trials conducted by the VRC Clinic at the NIH Clinical Center. A brief summary of each study to date follows. VRC 101 (06-I-0056) was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by the VRC and administered in a prime-boost regimen. VRC 601 (13-I-0189) is the first Phase I dose-escalation study in HIV-infected volunteers of a human monoclonal antibody developed by the VRC with broad HIV-1 neutralizing activity.

总结：该临床研究项目是针对HIV感染志愿者通过NIH临床中心VRC Clinic进行的临床试验进行的针对HIV的主动免疫（疫苗）和被动免疫（单克隆抗体）相关临床试验。 以下是迄今为止每项研究的简要摘要。 VRC 101（06-I-0056）是VRC开发的两种候选HIV-1疫苗的第一个I期治疗研究，并以初免-加强方案给药。 VRC 601（13-I-0189）是VRC开发的具有广泛HIV-1中和活性的人单克隆抗体在HIV感染志愿者中进行的第一项I期剂量递增研究。